Cigna earnings beat by $0.04, revenue topped estimates
VANCOUVER - Clearmind Medicine Inc. (Nasdaq:CMND), a micro-cap biotech company valued at $5.8 million, announced Wednesday the completion of site initiation at Tel Aviv Sourasky Medical Center (TASMC) for its Phase I/IIa clinical trial evaluating CMND-100 for Alcohol Use Disorder (AUD). The stock has shown strong momentum, gaining over 15% in the past week according to InvestingPro data.
The multinational trial is already underway at Yale School of Medicine and Johns Hopkins University in the United States, as well as TASMC and Hadassah-University Medical Center in Israel. The study aims to assess the safety, tolerability, and pharmacokinetic profile of CMND-100, while also exploring early efficacy signals such as reduced alcohol cravings and consumption in AUD patients.
Prof. David Zeltser, Director of the Emergency Medicine Department at TASMC, is leading the trial at the Tel Aviv site.
"This milestone brings us closer to potentially delivering an innovative, non-hallucinogenic treatment for AUD, addressing a critical unmet need for millions worldwide," said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, in the press release.
CMND-100, the company’s lead compound, utilizes the molecule 5-methoxy-2-aminoindane (MEAI). According to the company, preclinical studies have shown results in reducing alcohol cravings.
Clearmind Medicine is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics. The company claims its intellectual portfolio includes nineteen patent families with 31 granted patents.
Alcohol Use Disorder affects millions globally and accounts for 2.6 million deaths annually, according to the company statement.
In other recent news, Clearmind Medicine Inc. has made significant progress in its Phase I/IIa clinical trial for CMND-100, an oral treatment candidate for Alcohol Use Disorder (AUD). The company has expanded the trial to include a new clinical site at Johns Hopkins University School of Medicine, where the first participant has been enrolled. This expansion follows the dosing of the first participant at Yale School of Medicine’s Department of Psychiatry. Additionally, Clearmind has received Institutional Review Board approval from Tel Aviv Sourasky Medical Center, allowing patient enrollment at this site as well. The trial is also being conducted at Hadassah-University Medical Center in Jerusalem, which was recently added as a clinical site. The trial aims to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100, while also assessing preliminary efficacy indicators for reducing alcohol cravings and consumption. These developments mark a step forward in Clearmind’s efforts to advance its treatment for AUD.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.